Merganser Biotech Inc. raises $28 million to develop hepcidin mimetic peptides
February 19, 2015 - Merganser Biotech Inc. has raised $28 million in a Series A financing round. The round was led by the Novartis Venture Fund, joined by Frazier Healthcare, Sutter Hill Ventures and Osage University Partners. Seed investors BioAdvance and Stateside Developments also participated in the round. The proceeds from this financing will be used to develop hepcidin mimetic peptides as therapeutics for the treatment of rare hematological and iron overload diseases.
Read more here